Filana Therapeutics Q3 2026 Net Loss Narrows to $10.73 Million
- Filana Therapeutics’ third-quarter 2026 net loss narrowed year over year to $10.73 million.
- General and administrative expenses fell 6% to $7.4 million due primarily to lower stock-based compensation expenses.
- Patient screening for the Phase 2a simufilam study in TSC-related epilepsy is expected to begin by the first quarter of 2027.
- Cash totaled $47 million at September 30, 2026, with year-end cash and cash equivalents projected at $38 million to $42 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Filana Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050800PRIMZONEFULLFEED9870920) on November 05, 2026, and is solely responsible for the information contained therein.